View
3
Download
0
Category
Preview:
Citation preview
Role of FDA in Guiding Role of FDA in Guiding Drug DevelopmentDrug Development
Carl Peck, MDUCSF Center for Drug Development ScienceUC-Washington Center,Washington DC
Department of Biopharmaceutical SciencesSchool of Pharmacy, University of California San Francisco
DTRCS Regulatory Education Seminar, June 12, 2007
Copyright © Carl Peck, All Rights Reserved
??WhyWhy FDA ?
WhenWhen does FDA get involved ?
HowHow does FDA guide drug development?
WhatWhat comprises FDA guidance ?
WhatWhat’’s news new at FDA ?
Copyright © Carl Peck, All Rights Reserved
WhyWhy FDA ?
FD&C Act: history and its supportersresulted from public safety events or public health challenges
~ 1902/6, 1938, 1962, 1972, 1984, 1987, 1997, 2004-2007a uniquely American phenomenon
Investment in FDAPoliticization
Evolution of Drug Regulation (R. Temple)SAFETY EFFECTIVENESS INDIVIDUALIZATION
….. PERSONALIZATION SAFETY
Copyright © Carl Peck, All Rights Reserved
WhenWhen does FDA get involved ?
Preclinical (on request) phaseIND requirements for CMC, animal testing, design of Phase 1 clinical studies
IND phaseType A, B, C meetings
NDA review phaseMeetings + many communications
Marketing phaseADR surveillancenew uses, product changes, withdrawals
Copyright © Carl Peck, All Rights Reserved
FDA Initiative: Innovation vs Stagnation -Challenge & Opportunity on the CriticalPath to New Medical Products, March 2004
Copyright © Carl Peck, All Rights Reserved
End of Phase 2a meetingEnd of Phase 2a meeting
Two Year’s Experience Reviewed at FDA Pharmaceutical Sciences AdvisoryCommittee Meeting, November 14, 2005
http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4194S1_Slide-Index.htm
Copyright © Carl Peck, All Rights Reserved
End of Phase 2a MeetingsEnd of Phase 2a MeetingsPurposePurpose: ↓ Late phase clinical trial (2b, 3) unnecessary failure
FormatFormat: non-binding scientific interchange.
DeliverablesDeliverables: Perform modeling (relevant phase 1/2a data) & simulation of next trial design employing
Mechanistic or empirical drug-disease modelPlacebo effect (magnitude & time-course)Rates for dropout and compliance. (prior FDA experience)
Recommendation on sponsors trial design + alternative including patient selection, dosage regimen,…Answers to other questions from the clinical and clinical pharmacology development plan
TimeTime--coursecourse: ~ 6 weeks
Key sponsor & FDA participantsKey sponsor & FDA participants: physician, biostatistician, clinical pharmacology (pharmacometrics), project management
Adapted from R. Powell, FDA
Copyright © Carl Peck, All Rights Reserved
HowHow does FDA guide drug development ?
Written guidancesRegulations, guidelines (incl. ICH), guidancesLiterature publicationsRegulatory letters(Statute, Congressional Reports)
Face-to-face & telephonic meetingsPre-IND, EoP2, EoP2a, EoP2, pre-NDA, others as-needed
FDA Advisory Committee meetingsPodium presentationsPodium presentations
Website - www.fda.gov
Copyright © Carl Peck, All Rights Reserved
Of about a total of 244 NDAs, 42 included a pharmacometrics component….
Pharmacometric analyses were pivotal in regulatorydecision making in more than half of the 42 NDAs.
Of 14 reviews that were pivotal to approval decisions,… 6 reduced the burden of conducting additional trials.
AAPS Journal 2005;7 (3) Article 51 (AAPS Journal 2005;7 (3) Article 51 (www.aapsj.orgwww.aapsj.org))
Copyright © Carl Peck, All Rights Reserved
WhatWhat comprises FDA guidance ?
Standardschemistry and manufacturing controls (CMC)preclinical animal toxicology requirementsethics of human clinical trialsdocumentary requirements for INDs, & NDAsElectronic records (21 CFR part 11)
Clinical trialssafetyeffectivenesstrial design
Copyright © Carl Peck, All Rights Reserved
How many How many guidancesand are they binding ?
GUIDANCES> 500 > 500 guidancesguidances (final/draft, FDA/ICH)
Guidance documents:Cannot legally bind FDA or the publicRecognizes value of consistency & predictabilityBecause companies want assuranceSo staff will apply statute & regulations consistently
www.fda.gov/cder/guidance.htm
Copyright © Carl Peck, All Rights Reserved
Planned Guidances (as of 2000)
Guidances by Category
0102030405060708090
100A
dver
tisin
gB
ioph
arm
Che
mis
try
Clin
Ant
imic
Clin
Med
Clin
Pha
rmC
ompl
ianc
eEl
ec S
ubm
Gen
eric
ICH
Indu
stry
Labe
ling
OTC
Phar
m/T
oxPr
ocdu
ral
Use
r Fee
Category
# of
Gui
danc
es
PlannedTo Date
Copyright © Carl Peck, All Rights Reserved
ClinicalClinical PharmacologPharmacologyy GuidancesGuidancesDrug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro (97); In Vivo (99) Pharmacokinetics in Patients w/renal & impaired hepatic function: study design, data analysis, dosing/labelingPediatric Pharmacokinetic Studies for Drugs BiologicalPopulation Pharmacokinetics ( 99)Exposure-Response (02) Exploratory IND Studies (April 2005)Exploratory IND Studies (April 2005)
Copyright © Carl Peck, All Rights Reserved
Copyright © Carl Peck, All Rights Reserved
GoalsGoals of the Exploratory INDReduce time & resources on drugs unlikely to succeed
Select most likely to succeed from group of candidate drugsTo learn PK, biodistribution, mechanism of actionReduced preclinical requirements due to less risk
Copyright © Carl Peck, All Rights Reserved
Exploratory IND
“Phase 0” studies – prior to traditional drug development Phase I trials
Microdose, sub-pharmacologic or pharmacologic dose
Single dose or limited period of administration
Copyright © Carl Peck, All Rights Reserved
Types of Exploratory Studies
Single DosePK, Imaging
Multiple DosePharmacological, Pharmacodynamic endpoints
Copyright © Carl Peck, All Rights Reserved
RequirementsRequirementsCMC
GLP (+/-)Incomplete impurity profileSummary report
Toxicology - depends upon goalSingle Dose - 1/100 est. pharmacological dose or < 100 ug
Single species (rodent), 14 day observationMultiple Dose (<1/50 NOAEL + max 1/4 of 2 wk NOAEL)
Two species, 14 day repeat dose
Copyright © Carl Peck, All Rights Reserved
Copyright © Carl Peck, All Rights Reserved
Copyright © Carl Peck, All Rights Reserved
Clinical/Medical Clinical/Medical GuidancesGuidances
Providing Clinical Evidence of Effectiveness for Providing Clinical Evidence of Effectiveness for Human Drug and Biological ProductsHuman Drug and Biological Products (98)(98)
Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs (93) Study of Drugs ... used in the Elderly (89) Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: Exception from Informed Consent Requirements for Emergency Research
Copyright © Carl Peck, All Rights Reserved
Statutory Guidance: Statutory Guidance: FDA Modernization Act of FDA Modernization Act of 19971997 -- ““FDAMAFDAMA””
Sec. 111. Pediatric studies of drugsPK bridging studies
Sec. 115a. Clinical investigations support of one adequate and well-controlled clinical investigation by “confirmatory evidence” comprising PK or PK/PD
Copyright © Carl Peck, All Rights Reserved
Pediatric Labeling Pediatric Labeling RegulationsRegulations“FDA may approve a drug for pediatric use based on ...
studies in adults, with other information supporting pediatric use…. additional information supporting pediatric use must ordinarily include data on the pharmacokinetics of the drug in the pediatric population ….Other information, such as data on pharmacodynamic studies…..”
(21 CFR 201.56)
Copyright © Carl Peck, All Rights Reserved
FDAMA, Sec. 115aFDAMA, Sec. 115aClinical investigationsClinical investigations“If the Secretary determines, based on based on relevant sciencerelevant science, that
data from oneone adequate and welladequate and well--controlled clinical controlled clinical investigationinvestigation and confirmatory evidenceconfirmatory evidence …. are sufficient to establish effectiveness, the Secretary may consider such data and evidence to constitute substantial evidence..”
Copyright © Carl Peck, All Rights Reserved
FDAMA, Sec. 115aFDAMA, Sec. 115aCONGRESSIONAL CONGRESSIONAL COMMITTEE REPORTSCOMMITTEE REPORTS
““confirmatory evidenceconfirmatory evidence”” = ““scientifically sound data from scientifically sound data from any investigationany investigation in the NDA that provides substantiation as to the safety and effectiveness of the new drug”
confirmatory evidence = “consisting of earlier clinical trials, pharmacokineticpharmacokinetic data, or other appropriate scientific studies”
1 House Commerce Committee, 10/7/97, and Committee of Conference on Disagreeing votes of the two Houses, 11/9/97
Copyright © Carl Peck, All Rights Reserved
New Formulations and Doses New Formulations and Doses of Already Approved Drugsof Already Approved DrugsWhere blood levels ... are not very different, it may be possible to conclude ... is effective on the basis of pharmacokinetic dataalone.
Even if blood levels are quite different, if there is a well-understood relationship between blood concentration and response, ..., it may be possible to conclude ... is effective on the basis of pharmacokinetic data without an additional clinical efficacy trial.
Guidance for Industry “Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products”, May 1998
Copyright © Carl Peck, All Rights Reserved
Copyright © Carl Peck, All Rights Reserved
FDA FDA –– whatwhat’’s new?s new?Leadership
Commissioner Eschenbach, (Crawford), (McClellan), (Henney), (Kessler)Deputy Commissioner (Woodcock)
SafetyDrug withdrawals (Vioxx et al) (04)
Safety Oversight Board (05)Safety Oversight Board (05)PDUFA renewal 2007PDUFA renewal 2007
Initiatives Improving drug development
FDA leadership to improve drug development (2003)FDA leadership to improve drug development (2003)Critical Path Initiative (2004)Critical Path Initiative (2004)
EndEnd--ofof--Phase 2a (EOP2a) meeting (04)Phase 2a (EOP2a) meeting (04)ModelModel--based Drug Development (05)based Drug Development (05)Critical Path Opportunities List (06)Critical Path Opportunities List (06)
Copyright © Carl Peck, All Rights Reserved
Copyright © Carl Peck, All Rights Reserved
Adapted From Colin Garner: “R&d expenditure is increasing whilst Productivity is falling”
Copyright © Carl Peck, All Rights Reserved
PrototypeDesign orDiscovery
Clinical DevelopmentBasicResearch
FDA Filing/Approval &Launch
PreclinicalDevelopment
MarketApplication Approval
CRITICAL PATH
Adapted from S. Buckman: “Biomarkers 101”, RAPS, 2006
Copyright © Carl Peck, All Rights Reserved
Coordinate collaborative efforts“toolkits” for better product developmentEncourage academic interestOpportunities to share existing knowledge & databasesDevelop enabling standards
Guiding Principles Guiding Principles of Critical Path Initiativeof Critical Path Initiative
Adapted from S. Murphy: “FDA Update on Critical Path Initiative”, RAPS 2006, & FDA Critical Path Initiative 2004
Copyright © Carl Peck, All Rights Reserved
Organization of Critical Path Initiative within FDA
Commissioner’s Office: Office of Critical Path ProgramsCritical Path Steering Committee
CDER: Office of Translational SciencesClinical PharmacologyBiostatisticsCritical Path InitiativesIntramural Research
Copyright © Carl Peck, All Rights Reserved
http://www.fda.gov/oc/initiatives/criticalpath/
Copyright © Carl Peck, All Rights Reserved
Copyright © Carl Peck, All Rights Reserved
Critical Path InitiativeCritical Path InitiativeSix Priority Public Health ChallengesSix Priority Public Health Challenges
BiomarkerBiomarker developmentStreamlining clinical trialsclinical trialsBioinformaticsBioinformaticsEfficient, quality manufacturingmanufacturingantibiotics and countermeasures to combat emerging infectionsinfections and bioterrorismbioterrorismDeveloping therapies for children and adolescentschildren and adolescents
Copyright © Carl Peck, All Rights Reserved
Copyright © Carl Peck, All Rights Reserved
Copyright © Carl Peck, All Rights Reserved
http://www.fda.gov/oc/initiatives/criticalpath/opportunities06.html
Copyright © Carl Peck, All Rights Reserved
Critical Path Collaborations Critical Path Collaborations with NIHwith NIH
Joint workshops with FDAGenetic basis of Adverse Events –December 11&12, 2006Imaging in Alzheimer’s Disease
Drug development education for NIHNIAIDNational Institute on AgingIndividual Scientist Assistance
Copyright © Carl Peck, All Rights Reserved
Public/Private PartnershipsPublic/Private Partnerships
Predictive Safety Testing ConsortiumCDER-OCP, CPath Institute, 15 pharma firmsPre-clinical toxicogenomic biomarkers
Nephrotoxic biomarkers expected early 07Biomarker Consortium
NIH/ PhRMA/ FDA/CMSregulatory pathway for biomarker validation
FDG-PET in NHLOncology Biomarker Qualification Initiative
FDA, NCI and CMS Microarray Quality ConsortiumDuke/FDA ECG Collaboration
Copyright © Carl Peck, All Rights Reserved
Some Final Observations Some Final Observations FDA regulation is science-based
Advances innovation Facilitates needed drugs for patients
FDA clinical guidances are increasingly based on principles of clinical pharmacologySocial value: “guidance” versus “regulation”FDA guidance
national “treasure” versus “national nuisance”a bargain !
Copyright © Carl Peck, All Rights Reserved
End of PresentationEnd of Presentation
Recommended